nLife Therapeutics, S.L., a Granada, Spain-based company that develops innovative tratments for CNS diseases, has raised €5m in funding.
Backers include la Caixa, which made the investment through Caixa Capital Risc and Caixa Capital Biomed, and Invercaria, Inversión y Gestión de Capital Riesgo de Andalucía, S.A.U., which made the investment through the Jeremie fund.
They invested €2.5m each.
The company intends to use the funds to advance clinical trials for its treatments.
nLife Therapeutics is working on next generation targeted nucleic acids products. Its technology delivers conjugated nucleic acids with small chemicals to selected neurons after a single intra-nasal application.
It has launched siRNA based programs for Parkinson, Morbid Obesity and Major Depression Disorder (MDD).